Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Nature Communications|February 28, 2024
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATELavinia Tan, Chris Brown, Antony Mersiades, et al.
Endocrine-Related Cancer|October 5, 2017
TERT structural rearrangements in metastatic pheochromocytomasTrisha Dwight, Aidan Flynn, Kaushalya Amarasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2020
Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint InhibitorsJenny H Lee, Alexander M Menzies, Matteo S Carlino, et al.
Nature Communications|August 10, 2023
Copy number architectures define treatment-mediated selection of lethal prostate cancer clonesA M Mahedi Hasan, Paolo Cremaschi, Daniel Wetterskog, et al.
Cold Spring Harbor Molecular Case Studies|April 3, 2019
Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastasesMark J McCabe, Mark Pinese, Chia-Ling Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2020
Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination ImmunotherapyGabriela Marsavela, Jenny Lee, Leslie Calapre, et al.
Nature Communications|March 18, 2017
Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemiaPaul Yeh, Tane Hunter, Devbarna Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driverCatherine Emmanuel, Yoke-Eng Chiew, Joshy George, et al.
Nature Communications|June 17, 2026
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trialSarah M H Einerhand, Hamza Ali, Stephen Q Wong, et al.
Nature Medicine|November 21, 2018
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphomaRishu Agarwal, Yih-Chih Chan, Constantine S Tam, et al.
Pageof 6